GSK_Annual_Report_2021

Message from the Managing Director We wish to provide a commitment to all our stakeholders that GSK will remain well equipped to continue to deliver on our responsibilities to play a meaningful role in contributing to the wellbeing of the country. Dear Shareholders, “Accelerating access. Delivering hope.” best summarises your company’s response to the COVID-19 pandemic that brought economic activity around the world and India to a near-standstill. On behalf of the Board of Directors, I would like to say how proud I am of our colleagues, particularly our field-force, manufacturing and distribution teams, who went above and beyond their call of duty to keep our people safe and also deliver business. By being closely associated with our core purpose, our biggest contribution has been to accelerate and enhance access to healthcare, while delivering hope to patients. Through our medicines and vaccines, we improved the health of people in India. During the year under review (Apr’20-Mar’21), we delivered 0.9 billion packs of medicines and over 5.1 million vaccine doses (IQVIA March 2021 dataset). This was even more exceptional considering the current challenging times we were all going through and were concerned about the safety and wellbeing of our families and loved ones. I would also like to thank the India Leadership Team (ILT) for their leadership and foresight to look after and care for their teams. Given these circumstances, the financial results delivered have been nothing less than remarkable. Notwithstanding the challenges posed by disrupted supply chains and production lines due to the pandemic, your company adopted tireless efforts to keep the operations up and running. Our manufacturing facilities and workplaces attempted their best to ensure that our manufacturing and distribution networks operated at full capacity. At the same time, your company’s foresight in adopting digital transformation and consolidating its reach through multi-channel marketing helped us connect with Health Care Professionals (HCPs) remotely and expand our touchpoints on a variety of platforms. We leveraged this approach to further build on our partnerships with leading professional healthcare bodies. This helped us drive engagement on several initiatives that included appropriate administering and usage of antibiotics in the wake of COVID-19 and anti-microbial resistance (AMR). This year we began a new chapter on our diversity and inclusion journey as we were recognised for our tireless efforts. We received the recognition for being one of the “100 Best Companies for Women” by Working Mother and AVTAR, and one of the “Best Workplaces for Women” by Great Places to Work. We were also named as “one of the top employers in the India Workplace Equality Index (IWEI)”, India’s first comprehensive index for measuring LGBT+ inclusion. Another prime highlight of the year was the rolling out of the ‘GSK Culture Survey’ to obtain feedback from employees and elicit their views on future ways of working and collaboration. For your company, the engagement scores of the above survey remained greater than 95% even amid challenging times, highlighting our strong connect with our employees. FY 2021-22 is expected to be a promising year for your company. We remain set to introduce new assets during the next year to reiterate your company’s position as a science- and innovation-led pharmaceutical major. Towards this goal, your company will continue to work with partners and stakeholders, supporting one another and the communities we operate within to deliver value for our shareholders. We wish to provide a commitment to all our stakeholders that GSK will remain well equipped to continue to deliver on our responsibilities to play a meaningful role in contributing to the wellbeing of the country. We believe your company is well placed to deliver on its long-term strategic ambitions and its core purpose. Sridhar Venkatesh 3 Annual Report 2020-21